Reduced Tumor Necrosis Factor Receptor–Associated Death Domain Expression Is Associated with Prostate Cancer Progression

Diping Wang,1 R. Bruce Montgomery,2 Lucy J. Schmidt,1 Elahe A. Mostaghel,2,3 Haojie Huang,1 Peter S. Nelson,2,3 and Donald J. Tindall1

1Departments of Urology Research/Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota; 2Departments of Medicine, University of Washington School of Medicine and 3Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; and 4Cancer Center, University of Minnesota, Minneapolis, Minnesota

Abstract

By using LNCaP and its derivative cell lines, we first observed an association between tumor necrosis factor-α (TNF-α) resistance and hormone independence. Moreover, we found that the expression of tumor necrosis factor receptor–associated death domain (TRADD) was reduced in androgen deprivation–independent cells compared with that in androgen deprivation–dependent cells. TRADD is a crucial transducer for TNF-α–induced nuclear factor-κB (NF-κB) activation. Knocking down TRADD expression in LNCaP cells impaired TNF-α–induced NF-κB activation and androgen receptor repression, whereas overexpression of TRADD in C4-2B cells restored their sensitivity to TNF-α. Finally, we found that androgen deprivation reduces TRADD expression in vitro and in vivo, suggesting that androgen deprivation therapy may promote the development of TNF-α resistance by reducing TRADD expression during prostate cancer progression. [Cancer Res 2009;69(24):9448–56]

Introduction

Prostate cancer is the most common malignancy and one of the leading causes of cancer death in North American men. Initially, most prostate cancers are responsive to androgen deprivation therapy, which is achieved by chemical or surgical castration. However, these cancers relapse eventually and ultimately progress to castration-recurrent disease that is resistant to not only hormone deprivation therapy but also other systemic chemotherapy (1, 2). Nonetheless, androgen receptor (AR) signaling remains critical for castration-recurrent prostate cancers (3, 4).

The tumor necrosis factor α (TNF-α) pathway is also aberrantly regulated during prostate cancer progression (5). TNF-α is a pleiotropic cytokine that exerts a variety of functions in inflammation, immunity, cell differentiation, cell proliferation, and, paradoxically, cell death (6). TNF-α is primarily produced by immune cells. However, it is also produced by numerous other cell types, including epithelial cells of human prostate cancer (7). TNF-α binds to the TNF-α receptor (TNFR1), leading to phosphorylation, ubiquitination, and proteasome-mediated degradation of the inhibitor of NF-κB (IκB), which binds to and inhibits nuclear factor-κB (NF-κB) activation by forming a complex in the cytoplasm. Degradation of IκB results in the release of NF-κB, which then translocates to the nucleus. In the nucleus, NF-κB regulates the transcription of target genes, which promote cell proliferation or inflammatory responses. In most cells, TNF-α activates caspase-8 and induces apoptosis only when NF-κB activation is hampered (8). However, in prostate cancer LNCaP cells, even if NF-κB signaling is activated, TNF-α can still induce cell death in a dose-dependent manner (9). This apparent discrepancy may be explained by the negative regulation of AR expression and activity by NF-κB (10, 11). Interestingly, androgen deprivation–independent (AI) prostate cancer cells are mostly resistant to TNF-α, whereas androgen deprivation–dependent (AD) cells are sensitive to it, suggesting an association between androgen deprivation and TNF-α susceptibility (12). However, it remains unclear how prostate cancer cells lose their sensitivity to TNF-α as they progress.

Tumor necrosis factor receptor–associated death domain (TRADD) was one of the first identified TNF-R1–associated proteins (13). TRADD contains a COOH-terminal death domain that is 23% identical to the death domain of TNFR1 and can directly interact with TNFR1 (13). The NH2 terminus of TRADD interacts with the TNFR-associated factors TRAF1 (14), TRAF2 (15), and TRAF3 (16). Thus, TRADD mediates TNF-R1–induced apoptosis as well as NF-κB activation (13). Recent knockout studies also revealed TRADD-mediated functions in Toll-like receptor signaling and antiviral immune responses (17, 18).

In this article, we report an association between reduced TRADD expression and TNF-α resistance in AI prostate cancer cell lines. Our data show that TRADD is critical for TNF-α–induced NF-κB activation and AR suppression in prostate cancer. Furthermore, we show that androgen deprivation decreases TRADD expression in vitro and in vivo, suggesting that prostate cancer cells may lose their TNF-α sensitivity after androgen deprivation therapy.

Materials and Methods

Materials. LNCaP were purchased from the American Type Tissue Collection. C4, C4-2, and C4-2B cells were purchased from ViroMed Laboratories. peDNA wild-type (wt)–TRADD and TRADDΔ301 were gifts from Dr. T. Tsuruo (University of Tokyo, Tokyo, Japan). pcDNA IκBα SS/AA was a gift from Dr. D.D. Billadeau (Mayo Clinic, Rochester, MN). siRNA-A (no target siRNA), RIP siRNA (h2), and TRADD siRNA were purchased from Santa Cruz Biotechnology.

The following antibodies were used in this study: anti-AR (p21; Millipore); anti–prostate-specific antigen (PSA; c-19), anti-ERK2 and anti–receptor-interacting protein 1 (RIP1; k-20; Santa Cruz Biotechnology); anti–phospho-IκBα (Ser32/36; 5A5), anti-Lamin A/C, and anti–α-tubulin (Cell Signaling); anti–TRADD, anti–IκBα, and anti–NF-κB p65 (BD Transduction Laboratory); anti–FAS-associated death domain (FADD; BD Pharmingen); and anti–TNFα neutralizing and anti–TNF-R1 (R&D Systems).

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Requests for reprints: Donald J. Tindall, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-8553; Fax: 507-284-2384; E-mail: tindall@mayo.edu.

©2009 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-09-1903


Published OnlineFirst November 24, 2009; DOI: 10.1158/0008-5472.CAN-09-1903
Recombinant human TNF-α was purchased from Chemicon. Dutasteride was obtained from GlaxoSmithKline. Methyltrienolone (R1881) was pur-
chased from DuPont.

RNA isolation, amplification, and quantitative reverse transcriptase-
PCR. Total RNA from cultured cells was isolated by Trizol (Invitrogen)
according to the manufacturer’s instructions. cDNA was prepared from
5 μg total RNA using the SuperScript III first-strand synthesis system
(Invitrogen) following the manufacturer’s instructions.

Tissues obtained at prostatectomy were frozen in optimal cutting temper-
ature (OCT; Tissue Tek OCT, Sakura Finetek). Frozen prostate samples
embedded in OCT were used for separate laser capture microdissec-
tion of stroma, benign and malignant epithelium as indicated. Approximately
2,000 to 3,000 cells per sample were collected using the Arcturus Veritas
LCM System and used for isolation of total RNA followed by two rounds
of linear amplification as we have previously described (19, 20). Primers
specific for genes of interest were designed using the National Center
for Biotechnology Information Web-based primer design tool Primer-BLAST.2
First-strand cDNA templates were generated from 1 μg of amplified RNA
using 1 μg of random primers (Invitrogen) and SuperScript II reverse tran-
scriptase (Invitrogen).

Quantitative reverse transcriptase-PCR (qRT-PCR) was performed with
SYBR green PCR Master Mix (Applied Biosystems) on an Applied Biosys-
tems System Sequence Detector 7700HT. All reactions were assessed for
quality by examination of both amplification and dissociation curves. Sam-
ple were normalized using glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) or RPL13A.

Primers sequences used in these study are the following: AR Fwd, GGAA-
CAGCAGGACCTCTCAGGC; AR Rev, CTGTTAAGGTCGCGCAAAGC; TRADD
Fwd, CGCATAGCTTTTGTTTGAGCT; TRADD Rev, CGTTGGACTCTCGAG-
CAGTCT; RPL13A Fwd, CCTGAGCGAGAAGGAGAAGAGA; RPL13A Rev
TTGAGACCTCTTGTTATGTGCAA. Human GAPDH primers were
purchased from Applied Biosystems.

Cell lysate preparation and Western blotting assays. Whole-cell ly-
sates were prepared in radioimmunoprecipitation assay buffer with a com-
plete protease inhibitor cocktail (Santa Cruz Biotechnology). Nuclear and
cytoplasmic protein fractions were prepared with a Nuclear Extraction kit
according to the manufacturer’s instructions (Millipore). Equal amounts of
protein (30–80 μg) were loaded onto 10% NuPage Bis-Tris gels (Invitrogen),
and electrophoresis was performed according to the manufacturer’s in-
structions. Proteins were blotted onto nitrocellulose membranes. Blots
were probed with antibodies to evaluate protein expression.

Transfection and luciferase assay. Transfections by electroporation
were performed as described previously (21). For luciferase assays, cells
were harvested 48 h after transfection. Firefly luciferase and Renilla luciferase activities in cell lysates were determined using a dual
reporter assay kit (Promega). Relative luciferase units were calculat-
ed as indicators of transcriptional activity.

Cell viability assay. Cells were seeded in 96-well tissue culture plates at
a density of 3,000 or 5,000 per well and treated as indicated (Invitrogen).
Cell viability was assessed with the Cell Titer 96 Aqueous One solution cell proliferation
assay (Promega) according to the manufacturer’s instructions. cDNA was prepared from
5 μg of amplified RNA
using 1 μg of random primers (Invitrogen) and SuperScript II reverse tran-
scriptase (Invitrogen).

Results

TNF-α reduces prostate cancer cell viability through inhibi-
tion of AR expression and activity. Although elevated TNF-α
has been documented in prostate cancers (7), the effects of TNF-α
on prostate cancer cells still mainly remain unclear. Thus, we
investigated the effect of TNF-α on the viability of LNCaP cells. The
results showed that TNF-α reduced LNCaP cell viability in a dose-
dependent manner (Fig. 1A). Given the fact that TNF-α activates
NF-κB in LNCaP cells, it is paradoxical that TNF-α reduces LNCaP
cell viability. Mizokami and colleagues (7) first reported that TNF-α
represses AR expression in LNCaP cells and suggested that this
might be the underlying mechanism by which TNF-α inhibits pros-
tate cancer cell growth and survival. To confirm the effect of TNF-α
on AR expression, we examined AR expression by Western blotting
after treating LNCaP cells with different doses of TNF-α. As ex-
pected, TNF-α reduced AR and PSA expression in a dose-dependent
manner (Fig. 1B). To confirm that AR reduction was indeed caused
by TNF-α, we used a TNF-α–specific antibody to neutralize TNF-α.
TNF-α–neutralizing antibody totally abolished the TNF-α–induced
reduction of IκBα, AR, and PSA expression (Fig. 1C, left). Real-time
qRT-PCR also showed that the TNF-α–neutralizing antibody
blocked the TNF-α–induced reduction of AR at mRNA level
(Fig. 1C, right). To assess whether TNF-α–induced downregulation
of AR leads to a suppression of AR transcriptional activity, we used
a PSA promoter–driven luciferase reporter to monitor AR tran-
scriptional activity. R1881, a synthetic androgen, greatly induced
AR transcriptional activity but cotreatment with TNF-α signifi-
cantly suppressed androgen-induced AR transactivation (Fig. 1D),
indicating that TNF-α negatively regulates AR transcriptional
activity.

TNF-α–induced AR repression requires NF-κB activation. Because NF-κB
has been suggested to mediate TNF-α–induced AR repression (11), we blocked NF-κB activation with an IκBα
super-suppressor (pcDNA-IκBα/ss/AA-HA) to test whether TNF-
α–induced AR suppression requires NF-κB activation (25). TNF-
α–induced reduction of AR and PSA expression was totally
blocked by an IκBα super-suppressor (Supplementary Fig. S1),
suggesting that NF-κB is required for TNF-α–induced downregu-
lation AR expression and activity.

AD and AI prostate cancer cells differentially respond to
TNF-α. To determine whether TNF sensitivity is altered during
prostate cancer progression, we used a prostate cancer cell line
progression model. The model is composed of LNCaP, C4, C4-2,
and C4-2B cell lines (26–28). LNCaP cells are sensitive to andro-
gen deprivation and have limited metastatic ability. On the other
hand, C4, C4-2, and C4-2B are resistant to androgen deprivation

and display more aggressive phenotypes. In many respects, the development of these AI cell lines recapitulates the progression of prostate cancer in vivo. Consistent with previous reports (9, 11), C4-2 and C4-2B are mostly resistant to TNF-α (Fig. 2A). In contrast to a nearly 50% reduction in LNCaP cells, TNF-α only reduced C4-2 and C4-2B cell viability by <20%, suggesting that prostate cancers may develop TNF-α resistance as they progress.

We then asked whether TNF-α–induced AR suppression is absent or limited in AI cell lines. We treated LNCaP and C4-2 cells with or without 20 ng/mL TNF-α and evaluated the expression of AR and PSA. In contrast to that in LNCaP cells, TNF-α–induced AR and PSA reduction was almost absent in C4-2 cells (Fig. 2B, left). A TNF-α dose-response assay indicated that even as high as 50 ng/mL, TNF-α still did not significantly reduce AR or PSA expression in C4-2B cells (Fig. 2B, right), confirming the resistance to TNF-α in AI cells. Given the critical role of NF-κB in TNF-α–induced AR repression, we speculated that NF-κB activation induced by TNF-α might be blocked or reduced in AI cells. Therefore, we compared the phosphorylation levels of IκBα in LNCaP and C4-2B cells after 1 hour of treatment with 20 ng/mL TNF-α. Consistent with the results of the NF-κB luciferase assay, TNF-α–induced phosphorylation of IκBα at serine 32 and serine 36 was significantly decreased (59%) in C4-2B cells compared with that in LNCaP cells (Fig. 2C). Accordingly, the reduction of total IκBα in LNCaP cells (51%, second lane versus first lane) was higher than that in C4-2B cells (34%, fourth lane versus third lane). We then compared TNF-α–induced NF-κB activity between these cell lines by a reporter luciferase assay. Consistent with the results of IκBα phosphorylation, TNF-α strongly induces NF-κB activation in LNCaP cells. Although TNF-α–induced NF-κB activation was not totally blocked in C4-2 and C4-2B cells, the amplitude of NF-κB activation was much lower than that in LNCaP cells (Fig. 2D), suggesting that TNF-α/NF-κB signaling pathway is impaired in AI cells. Collectively, these studies indicate that the TNF-α resistance in AI cells might be due to the impairment of the TNF-α/NF-κB signaling pathway.

TRADD expression level is correlated with TNF-α sensitivity in AD and AI prostate cancer cells. To explore the underlying mechanism by which AI cells develop increased resistance to TNF-α, we next examined the expression of TRFR1 in AD and AI cells. Consistent with previous studies (11, 29), TNFR1 expression was comparable at the protein level in all these cell lines (Fig. 3A). We then examined the expression of other important
signal transducers in the TNF-α signaling pathway, including TRADD, FADD, and RIP1. Interestingly, TRADD expression was significantly decreased in C4-2 and C4-2B cells compared with LNCaP cells, whereas RIP1 and FAS-associated death domain levels were comparable (Fig. 3A). To evaluate the mRNA level of TRADD, we designed a pair of TRADD-specific primers for real-time qRT-PCR assays. As shown in Fig. 3B, overexpressing TRADD increased both protein and mRNA levels of TRADD, whereas knocking down TRADD reduced both, suggesting that these primers are specific for TRADD. Using these primers, we then compared TRADD mRNA levels among these cell lines. Consistent with the protein level, the mRNA level of TRADD declined from LNCaP to C4-2B (Fig. 3C), suggesting a transcriptional regulation on TRADD during prostate cancer progression.

TRADD is critical for TNF-α-induced NF-κB activation and AR suppression. To test whether TRADD plays a critical role in TNF-α–induced NF-κB activation and AR suppression, we knocked down TRADD expression by TRADD siRNA in LNCaP cells. In TRADD-competent LNCaP cells, TNF-α treatment resulted in a strong IκBα phosphorylation, which consequentially reduced its expression (Figs. 2C and 4A). However, in TRADD knocked down cells, the TNF-induced IκBα phosphorylation was inhibited significantly (56% reduction). Accordingly, the total IκBα reduction was not as significant as that in TRADD-competent cells (Fig. 4A), suggesting that NF-κB activation is impaired in TRADD-deficient cells. To further confirm the role of TRADD in TNF-α–induced NF-κB activation, we evaluated NF-κB activity with a luciferase reporter assay. As shown in Fig. 4B, TNF-α–induced NF-κB activity was greatly inhibited in TRADD-deficient cells, demonstrating that TRADD is important for TNF-α–induced NF-κB activation.

However, knocking down TRADD did not completely block TNF-α–induced IκBα phosphorylation and NF-κB activation. It might be due to the limited efficiency of TRADD siRNA. More importantly, recent studies on TRADD knockout mice suggest that a strict dependence on TRADD for TNF-α–induced NF-κB activation is cell type specific (30). In cells with very low levels of RIP1, such as fibroblasts, TRADD deficiency almost completely abolishes TNFR1-mediated signaling. However, in cells with abundant RIP1 expression, such as macrophages, RIP1 is sufficient to mediate TNFR1 signaling in the absence of TRADD (17, 18). As shown in Fig. 3A, prostate cancer cells express abundant RIP1. Therefore, it is likely that RIP1 enables TNF-α to activate NF-κB at some level even in the absence of TRADD.

To determine whether TRADD is critical for the effects of TNF-α on AR suppression, we next evaluated the AR expression and activity after knocking down TRADD in LNCaP cells. As expected, knocking down TRADD almost abolished the AR reduction induced by TNF-α (Fig. 4C). Accordingly, PSA reduction was also abolished in TRADD-deficient cells. Furthermore, we evaluated the nuclear AR levels in TRADD-competent and TRADD-deficient cells. LNCaP were cultured in medium containing 9% charcoal-stripped serum (CSS) and treated with or without androgens and
TNF-α. Nuclear AR levels were assessed as indicators for AR activity. As expected, androgens greatly increased nuclear AR levels in cells transfected with control siRNA, but cotreatment with TNF-α significantly reduced the nuclear AR accumulation induced by androgens (Fig. 4D). However, in cells transfected with TRADD siRNA, TNF-α did not significantly reduce nuclear AR levels. To further confirm that TRADD is important for TNF-α-induced AR suppression, we performed immunofluorescence staining with an AR-specific monoclonal antibody to visualize AR expression and localization. As shown in Supplementary Fig. S2, AR was localized primarily within the cytoplasm in the absence of androgens. Androgen treatment resulted in increased AR expression and also translocation of AR into the nucleus. Cotreatment with TNF-α significantly suppressed androgen-induced AR translocation in TRADD-competent cells but not in TRADD-deficient cells, which is consistent with what we observed by nuclear AR Western blotting.

Collectively, these data suggest that TRADD plays a critical role in TNF-α-induced NF-κB activation and AR suppression. Interestingly, the TNF-α response pattern in TRADD knockdown LNCaP cells was very similar to that in C42B cells, implying that TNF-α resistance in AI cells may be due to loss of TRADD expression.

Ectopic expression of TRADD restores the TNF-α-induced AR repression in AI cells. To confirm that the reduced TRADD expression in AI cells contributes to the resistance to TNF-α-induced AR repression, we tested whether overexpression of TRADD in C4-2B cells could restore their TNF-α sensitivity. Because TRADD signals not only NF-κB activation but also cell apoptosis (13), we used two different TRADD constructs: wt-TRADD and TRADDΔ301. In the latter construct, 12 amino acids at the COOH-terminal end were deleted (31). Deletion of the COOH-terminal 12 amino acids abolishes its apoptosis-inducing ability but does not abolish the ability to activate NF-κB (13). As expected, overexpression of either wt-TRADD or TRADDΔ301 in C4-2B cells potentiated TNF-α to activate NF-κB (Fig. 5A), confirming that TRADD-mediated activation is independent of apoptosis. Similarly, ectopic expression of either wt-TRADD or TRADDΔ301 both enabled TNF-α to repress AR and PSA expression (Fig. 5B), suggesting that NF-κB activation, instead of apoptotic signals, mediates TNF-α-induced AR repression. Furthermore, ectopic expression of either wt-TRADD or TRADDΔ301 both re-sensitized C4-2B cells to TNF-α treatment (Fig. 5C). Because TRADDΔ301 lost its ability to directly induce apoptosis (31), the reduction of cell viability is most likely due to AR repression instead of TNF-α-induced apoptosis.

Androgen deprivation suppresses TRADD expression in vitro and in vivo. The next issue we addressed is to determine the mechanism underlying the reduced TRADD expression in AI cell lines. Because these cell lines were developed under selective pressure of androgen deprivation, we questioned whether androgen deprivation affects TRADD expression. We investigated TRADD expression in cells cultured in hormone-free medium and found that removal of hormone significantly reduced TRADD expression in LNCaP cells. Likewise, treatment with the antiandrogen bicalutamide or the SRD5A inhibitor dutasteride also significantly decreased TRADD expression (Fig. 6A, left), suggesting that androgens are required to maintain a high level of TRADD expression. Conversely, treatment with 1 nmol/L R1881 for 48 hours greatly increased TRADD expression, which could be blocked by bicalutamide (Fig. 6A, right).
To determine whether TRADD expression is affected by androgen deprivation in vivo, we evaluated TRADD expression in prostate tissue samples from a neoadjuvant clinical trial of dutasteride. As expected, following 4 months of dutasteride treatment, tissue dihydrotestosterone levels were significantly lower than that found in untreated prostates, with concomitant increases in tissue testosterone. However, TRADD transcript levels were not significantly different between prostate epithelial cells acquired from untreated and dutasteride-treated prostate tissue samples (Supplementary Fig. S3). As documented previously, although dutasteride lowers dihydrotestosterone levels, there are concomitant higher levels of testosterone. Thus, the lack of a dutasteride effect on TRADD in vivo might be due to high levels of testosterone. We next measured TRADD expression in radical prostatectomy samples resected from men treated with standard androgen deprivation therapy with the LHRH agonist lupilrolide and the antiandrogen bicalutamide, or with high doses of E2. Compared with transcript levels measured in benign untreated prostate epithelium, TRADD transcript levels in both benign (P < 0.001) and neoplastic epithelium (P < 0.04) treated with lupilrolide + bicalutamide or E2 were significantly lower than TRADD levels in untreated benign epithelium (Fig. 6B), confirming a critical role of androgen on TRADD expression. Interestingly, we also observed that in either the lupilrolide + bicalutamide or the E2 group, levels of TRADD transcripts in benign epithelium was lower than that in neoplastic epithelium (Fig. 6B), suggesting that TRADD is differentially expressed between normal and cancerous prostate tissues.

**Aberrant TRADD expression is associated with prostate cancer progression.** To further assess the expression of TRADD...
in human prostate cancers, we used laser capture microdissection to acquire benign and cancerous prostate epithelial cells from 14 individuals with localized prostate adenocarcinoma. We quantitated TRADD transcripts by qRT-PCR using the RPL13 mRNA as a reference control. Compared with benign epithelium, the expression of TRADD was significantly lower in cancerous epithelium ($P = 0.0138$; Fig. 6C).

Data from LNCaP cell line model suggested that TRADD expression might be altered as prostate cancers progress. To test whether TRADD expression is decreased during prostate cancer progression in vivo, we used the LuCaP 23.1 and LuCaP 35 prostate cancer xenograft models. LuCaP 23.1 and LuCaP 35 tumors grow in intact immunocompromised mice and serve as a model for prostate cancer progression (32, 33). Both original LuCaP 23.1 and LuCaP 35 tumors regressed after castration but eventually recurred and became AI tumors. TRADD immunohistochemistry staining show that the original LuCaP 23.1 and LuCaP 35 tumors (AD tumors) express relatively high levels of TRADD, but castration-recurrent LuCaP 23.1 Al and LuCaP 35 AI tumors express very little TRADD (data not shown; Fig. 6D). Thus, both cell line and xenograft models strongly suggest that TRADD expression might be reduced as prostate cancer progresses.

**Discussion**

It is well established that both androgen/AR and TNF-α/NF-κB signaling pathways are important for prostate cancer growth. The mutual inhibition between these two pathways has been documented (34–36). Consistent with these studies, we showed that TNF-α induces AR suppression in prostate cancer cells through NF-κB, which may mediate TNF-α-induced reduction in cell viability. Unlike in many other cell types, activation of NF-κB by TNF-α in prostate cells does not promote cell proliferation. Conversely, it has a proapoptotic effect (37). The mechanisms underlying this phenomenon are largely unknown. One potential mechanism is that NF-κB induces DR4 expression, which promotes TNF-related apoptosis inducing ligand (TRAIL)–induced cell death in prostate cancer cells (38). Our data suggest that TNF-α–induced AR suppression may be another important underlying mechanism.

In contrast to our finding, some other studies suggested that AR and NF-κB might enhance each other’s activity (39, 40). In a recent report, Jin and colleagues (41) observed that constitutive activation of NF-κB in prostate cancer xenografts (in which IκBα was knocked down) is correlated with increased AR expression, and their data implied that NF-κB RelA increases AR expression and contributes to prostate cancer progression. Chen and Sawyers (42) identified four NF-κB binding sites in the PSA core enhancer and showed that these sites are directly bound by NF-κB and activate PSA expression in the absence of androgen, suggesting that constitutively active NF-κB might contribute to prostate cancer progression. However, Cinar and colleagues (43) soon reported a fifth NF-κB binding site in the core of the PSA promoter, which is suppressive to AR transcriptional activity. Binding of p65, but not p50, to this site represses, instead of activates, AR-mediated PSA transcription. Collectively, the precise effect of TNF-α–NF-κB on AR activity still remains unclear and it is likely dependent on the specific cellular milieu.

The correlation between androgen deprivation resistance and TNF-α resistance in prostate cells has been documented (11, 12). Ko and colleagues (11) reported that increased B-Myb (a NF-κB coregulator) expression in AI cells affects the inhibitory effect of NF-κB on the AR promoter, providing a potential mechanism for TNF-α resistance in AI prostate cancer cells. In our study, we found an association between reduced TRADD expression and TNF-α resistance in prostate cancer cell lines. We also showed that TRADD plays an important role in mediating TNF-α–inducing AR suppression and that loss of TRADD expression is associated with TNF-α resistance. Finally, we provided evidence that androgen deprivation leads to a reduction of TRADD both in vivo and in vitro. Considering the critical role of TRADD in
Androgen deprivation reduces TRADD expression **in vitro** and **in vivo**.

**A.** Western blotting evaluating TRADD expression in LNCaP cells. *Left,* cells were cultured in CSS medium, treated with 10 μmol/L bicalutamide or 1 μmol/L dutasteride for 72 h as indicated; *right,* cells were grown in CSS medium and treated with or without R1881 and bicalutamide for 24 h. ERK2 serves as a loading control.

**B.** qRT-PCR quantitates TRADD mRNA levels in benign (Be) and cancerous (Ca) epithelium from radical prostatectomy samples resected from men treated with leuprolide (LU) or E2. RPL13 mRNA was used as a reference control.

**C.** TRADD mRNA levels in benign and cancerous prostate epithelial cells were evaluated by qRT-PCR. RPL13 mRNA was used as a reference control.

**D.** Immunohistochemistry (IHC) staining for TRADD (bottom) was performed in both LUCAP 23.1 AD (*left*) and LUCAP 23.1 AI (*right*) tumors along with H&E staining (*top*). Images were captured through a Zeiss Axioplan 2 light microscope (Carl Zeiss) under ×40 objective magnification by using a Zeiss Axiocam. Close-up images are shown at the bottom-left corners.
TNF-α-mediated signaling, we speculate that androgen deprivation therapy contributes to the development of TNF-α resistance during prostate cancer progression. Therefore, our findings provide a potential mechanism by which prostate cancer develops TNF-α resistance after androgen deprivation therapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


Acknowledgments

Received 5/27/09; revised 10/1/09; accepted 10/28/09; published OnlineFirst 11/24/09.

Grant support: National Cancer Institute grants CA125747, CA 121277, and CA49196; T.J. Martell Foundation; and Pacific Northwest Prostate Cancer Specialized Program of Research Excellence grant P50CA097247.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank T. Tsuruo, R.L. Vessella, and D.D. Billadeau for kindly providing experimental materials and Roger Coleman for assistance with analyses.


Downloaded from cancerres.aacrjournals.org on August 15, 2017. © 2009 American Association for Cancer Research.
Reduced Tumor Necrosis Factor Receptor–Associated Death Domain Expression Is Associated with Prostate Cancer Progression

Diping Wang, R. Bruce Montgomery, Lucy J. Schmidt, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-1903

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/11/24/0008-5472.CAN-09-1903.DC1

Cited articles
This article cites 43 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/24/9448.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.